CO
CODX.US Co-Diagnostics, Inc. Common Stock
- Market cap
- USD 2.30M
- P/E
- -
- P/B
- 0.25x
- ROE
- -307.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CODX.US undervalued?
Graham numberThe Graham number of Co-Diagnostics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Co-Diagnostics, Inc. Common Stock fundamental analysis
No fundamental analysis for Co-Diagnostics, Inc. Common Stock yet.
Co-Diagnostics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C,…
Full company profileCo-Diagnostics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Co-Diagnostics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 7.66K | 39.9K | 215K | 74.6M | 97.9M | 34.2M | 6.81M | 3.92M | 622K | 793K |
| Gross Profit | -37.5K | 7.36K | 30.5K | 103K | 58.0M | 86.3M | 28.7M | 2.63M | 2.92M | 400K | -271K |
| Operating Income | -1.69M | -4.56M | -6.12M | -5.89M | 41.7M | 46.1M | -27.0M | -42.7M | -40.1M | -31.3M | -28.9M |
| EBITDA | -1.65M | -6.60M | -6.09M | -6.02M | 41.8M | 46.0M | -10.3M | -36.9M | -36.2M | -47.4M | -27.8M |
| Net Income | -1.93M | -6.96M | -6.27M | -6.20M | 42.5M | 36.7M | -14.2M | -35.3M | -37.6M | -46.9M | -29.0M |
| EPS | -5.17 | -19 | -15 | -11 | 46 | 37 | -14 | -36 | -37 | -35 | -4.62 |
| Balance Sheet | |||||||||||
| Total Assets | 1.30M | 4.66M | 1.55M | 2.22M | 71.2M | 160M | 123M | 95.3M | 64.0M | 24.7M | 12.8M |
| Total Liabilities | 4.29M | 812K | 2.61M | 478K | 4.54M | 25.6M | 8.57M | 9.31M | 9.69M | 4.11M | 3.37M |
| Shareholders' Equity | -2.99M | 3.85M | -1.06M | 1.74M | 66.7M | 134M | 115M | 86.0M | 54.3M | 20.6M | 9.43M |
| Cash & Short-term Investments | 999K | 3.53M | 950K | 893K | 47.3M | 89.9M | 81.3M | 58.5M | 29.7M | 11.9M | 715K |
| Total Debt | 3.39M | - | 1.91M | - | - | - | 348K | 2.99M | 2.15M | 1.24M | 1.56M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.31M | -3.21M | -4.08M | -5.53M | 28.2M | 41.1M | 6.57M | -22.1M | -29.2M | -29.1M | -27.6M |
| Capital Expenditure | 12.2K | 129K | 41.3K | 113K | 774K | 669K | 1.43M | 1.37M | 748K | 700K | 234K |
| Free Cash Flow | -1.32M | -3.34M | -4.12M | -5.64M | 27.4M | 40.4M | 5.14M | -23.4M | -29.9M | -29.8M | -27.8M |
| Ratios | |||||||||||
| ROE | - | -180.7% | - | -356.6% | 63.7% | 27.3% | -12.4% | -41.1% | -69.3% | -227.3% | -307.4% |
| ROA | -148.8% | -149.3% | -403.8% | -279.7% | 59.6% | 22.9% | -11.6% | -37.1% | -58.8% | -189.5% | -226.5% |
| Net Profit Margin | - | -90,827.9% | -15,714.3% | -2,882.0% | 57.0% | 37.5% | -41.6% | -518.7% | -961.4% | -7,533.6% | -3,652.3% |
| Debt to Equity | - | - | - | - | - | - | 0.00x | 0.03x | 0.04x | 0.06x | 0.17x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Co-Diagnostics, Inc. Common Stock dividends
Co-Diagnostics, Inc. Common Stock has not paid dividends in the last 9 fiscal years.
Last stock split: 1:30 on Jan 2, 2026.
Who owns Co-Diagnostics, Inc. Common Stock
- Insiders 7.02%
- Institutions 5.88%
- Public & others 87.11%
- Shares outstanding 8.82M
- Free float 10.3M
Top funds holding CODX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 33.0K | 0.37% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 6.57K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 4.34K | 0.05% | 0.00% | Sep 2026 |
Top institutions holding CODX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 236K | 3.38% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 89.2K | 1.28% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 58.3K | 0.83% | 0.00% | Jun 2026 |
| Private Asset Group LLC | 39.4K | 0.56% | -4.83% | Jun 2026 |
| Millennium Management LLC | 32.0K | 0.46% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 31.2K | 0.45% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 25.6K | 0.37% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 19.8K | 0.28% | +1,977,500.00% | Jun 2026 |
| Virtu Financial LLC | 17.6K | 0.25% | 0.00% | Jun 2026 |
| UBS Group AG | 16.1K | 0.23% | +118.39% | Jun 2026 |
| State Street Corp | 14.8K | 0.21% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 12.5K | 0.18% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.88K | 0.04% | +3,169.32% | Jun 2026 |
| Global Retirement Partners, LLC. | 100.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 81.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 81.00 | 0.00% | +39.66% | Jun 2026 |
| Heritage Wealth Advisors, LLC | 17.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 10.00 | 0.00% | 0.00% | Jun 2026 |
| FMR Inc | 7.00 | 0.00% | 0.00% | Jun 2026 |
| Goss Wealth Management LLC | 6.00 | 0.00% | 0.00% | Jun 2026 |
Co-Diagnostics, Inc. Common Stock company profile
- Company name
- Co-Diagnostics, Inc. Common Stock
- Ticker
- CODX.US
- Exchange
- USA Stocks
- Listed since
- Jul 12, 2017
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 115
- Fiscal year end
- December
- Address
- 2401 S. Foothill Drive, Salt Lake City, UT, United States, 84109
- Phone
- 801 438 1036
- Website
- co-dx.com
About Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
Co-Diagnostics, Inc. Common Stock management
8- Mr. Dwight H. EganChairman, CEO & President · born 1953
- Mr. Richard David AbbottPresident · born 1972
- Mr. Daniel Bohrer CPAExecutive VP of Finance & Accounting and Principal Financial & Accounting Officer · born 1977
- Mr. David NielsenChief Operating Officer
- Mr. Christopher ThurstonChief Technology Officer
- Dr. Wesley C. Lindsey MBA, Ph.D.Chief Scientific Officer
- Dr. Mayuranki Almaula Ph.D.Senior Vice President of Overseas Operations & Strategic Alliances
- Mr. Seth EganChief Commercialization Officer & Strategy Officer